Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    The Schiehallion Fund

    MCap

    USD2,257m

    Last close

    USD2.20

    ▲ 157.80 (7,172.73%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    LM PAY

    MCap

    EUR24m

    Last close

    EUR37.60

    ▲ 4.00 (11.90%)

  • Sectors

    Sectors

    View All Sectors
  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

SynAct Pharma – executive interview

SynAct Pharma – executive interview

SynAct Pharma — 6 videos in collection

More on this equity

In this interview, we speak with Mads Bjerregaard, chief business officer of SynAct Pharma, about the latest analysis from the Phase IIb ADVANCE study and why it could shape the path forward for resomelagon in rheumatoid arthritis. Mads discusses how temporary inflammatory flare-ups may have distorted the placebo response, the statistically significant benefit seen after affected patients were excluded from the analysis, its implications for Phase III patient selection and why a longer 26-week study could better capture deeper clinical responses. We also explore the upcoming FDA Type C meeting, the potential for a direct move into Phase III and how the new analysis could strengthen SynAct’s partnering position. Finally, Mads outlines the company’s broader strategic options, including licensing, an outright sale of resomelagon and other potential transactions.

< Previous

You may also be interested in these:

Healthcare

SynAct Pharma – executive interview

Healthcare

SynAct Pharma – executive interview
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.